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ABSTRACT
The proportion of pathogens causing hospital-onset infections that are resistant to antimicrobial agents
continues to increase worldwide. Inadequate antimicrobial therapy is an important factor in the
emergence of resistance and is associated with increased mortality. In the USA in 2000, the National
Nosocomial Infections Surveillance system reported that >50% of Staphylococcus aureus isolates collected
from intensive care units were resistant to methicillin (MRSA). The emergence of community-acquired
MRSA is a new concern. MRSA are associated with adverse clinical outcomes and increased hospital
costs. The increasing prevalence of MRSA contributes to the use of glycopeptides; however, isolates with
intermediate and full resistance to vancomycin and teicoplanin are now being reported. Newer agents,
such as the oxazolidinone linezolid, are effective in the treatment of serious Gram-positive infections;
however, linezolid-resistant isolates of Enterococcus faecium, Enterococcus faecalis and S. aureus have been
reported. Therefore, there is an unmet clinical need for new agents with activity against Gram-positive
pathogens. Daptomycin, a lipopeptide with a novel mode of action, was recently approved for the
treatment of skin and soft tissue infections in the USA. The two case studies presented herein detail
experience with the use of daptomycin in the USA.
Keywords Vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, linezolid,
daptomycin
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INTRODUCTION
The proportion of Gram-positive pathogens caus-
ing hospital-onset infections that are resistant to
antimicrobial agents continues to increase (Fig. 1)
[1,2]. In the USA in 2000, >50% of Staphylococcus
aureus isolates causing infections in intensive care
units were resistant to methicillin (MRSA) [1].
Vancomycin-resistant enterococci (VRE), which
emerged in the late 1980s, are now endemic in
many hospitals with a prevalence of >25% repor-
ted for intensive care units in the USA in 2000 [1].
The prevalence of resistance among other patho-
gens is also of concern, with resistance shown to
have increased in 1999 when compared with the
previous 5 years (Fig. 2).
The identiﬁcation of MRSA that appears to be
community acquired is a worrying development.
In 1999, four cases of community-acquired MRSA
were reported in the mid-west USA [3]. All four
cases were paediatric patients, none of whom
had predisposing risk factors, and all died. In each
case there was a delay in receiving appropriate
therapy. Community-acquired MRSA isolates
have a unique chromosomal cassette known as
SCCmec IV, which is small (<25 kb), mobile, pro-
miscuous and has the mecA resistance gene [4,5].
Vancomycin-resistant enterococci are rarely
community acquired (at least in the USA) but
remain an important nosocomial pathogen [6].
VRE infections include urinary tract infections,
bacteraemia, endocarditis and wound infection.
INADEQUATE ANTIBIOTIC
THERAPY
Inadequate antimicrobial therapy is relatively
common, with studies generally reporting an
incidence of inappropriate antibiotic therapy of
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c. 30% (Fig. 3) [7–11]. This is worrying, given that
inadequate antimicrobial treatment is an import-
ant factor in the emergence of infections caused
by antibiotic-resistant bacteria [12]. Factors
associated with administration of inadequate
antibiotic therapy include presence of resistant
pathogens, prior antibiotic administration and
invasive procedures [7,11]. Other factors that
may contribute to inadequate antimicrobial treat-
ment include use of broad-spectrum antibiotics,
prolonged hospital stay and prolonged mechan-
ical ventilation.
Inadequate antibiotic therapy has been shown to
be associated with an increased mortality among
patients with bloodstream infections and nosoco-
mial pneumonia, including ventilator-associated
pneumonia (Fig. 4). These studies underscore the
importance of selecting the appropriate initial
antibiotic early in the course of the infection [7–11].
OUTCOME OF NOSOCOMIAL
INFECTIONS CAUSED BY RESISTANT
GRAM-POSITIVE PATHOGENS
The adverse outcomes of nosocomial infections
caused by resistant pathogens (MRSA and VRE)
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Fig. 3. Incidence of inadequate antibiotic therapy in hos-
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Fig. 1. Antimicrobial resistance among pathogens causing hospital-onset infections in the USA. http://www.csk.gov/
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include increased hospital mortality, length of
stay, and hospital and intensive care unit (ICU)
costs [13–15].
Two recent meta-analyses demonstrated that
bacteraemia caused by MRSA was associated
with signiﬁcantly higher mortality rates (29 and
36% respectively) than bacteraemia caused by
methicillin-susceptible Staphylococcus aureus (12
and 23% respectively) (Fig. 5) [16,17].
The occurrence of MRSA in surgical site infec-
tions has a signiﬁcant impact on clinical and
economic outcomes, notably an increase in post-
operative mortality. A cohort study of patients
undergoing surgery at a large academic medical
centre and a regional community hospital,
between 1994 and 2000, prospectively identiﬁed
those who developed surgical site infections
caused by S. aureus, to assess the impact of
methicillin resistance (Table 1) [13]. Mortality
during the 90-day postoperative period was
signiﬁcantly higher in patients with surgical site
infections due to MRSA compared with patients
with MSSA (OR 3.6; 95% CI, 1.7–7.4; p < 0.001).
Given that comparing patients with such severe
infections can be difﬁcult, as the underlying
disease is an inﬂuential factor in determining
outcome, multivariate analysis which was ad-
justed for other predictors of mortality (age,
physical status and duration of surgery) was also
used. The impact of MRSA on 90-day mortality
remained signiﬁcant (OR 3.4; 95% CI, 1.5–7.2;
p ¼ 0.003). The median length of stay after
surgery and after documentation of the infection
was signiﬁcantly longer (p < 0.001 and p ¼ 0.001
respectively) for patients with MRSA [13].
Engemann et al. [13] also determined that
hospital costs were signiﬁcantly higher for
patients with surgical site infections due to MRSA
compared with MSSA (p < 0.001). Even after
adjusting for duration of surgery, hospital, length
of hospitalisation/ICU stay before infection,
diabetes and renal disease, infection with MRSA
was associated with signiﬁcantly higher hospital
costs (p ¼ 0.03).
Against the backdrop of the increasing preval-
ence of MRSA, the glycopeptides vancomycin and
teicoplanin are seen as the last choice for therapy.
However, resistance to both these antimicrobial
agents among Gram-positive pathogens has been
reported. Table 2 shows the characteristics of
teicoplanin-resistant S. aureus isolates from two
patients from the UK [18]. The MICs of teicopl-
anin against the isolates were 16 mg/L in one
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Fig. 5. Association between mortality and infection with
methicillin resistant Staphylococcus aureus: two meta-analy-
ses. Data from reference [16]a and reference [17]b.
Table 1. Comparison of clinical parameters and hospital
costs among patients with surgical site infections caused
by methicillin-susceptible (MSSA) and methicillin-resistant
(MRSA) Staphylococcus aureus
MSSA
(n ¼ 165)
MRSA
(n ¼ 121) p-value
Clinical parameter
Mortality,
90 days
6.7% 20.7% <0.001
Length of stay, median days
After surgery 14 (7–25) 23 (12–38) <0.001
After infection 10 (4–17) 15 (7–30) 0.001
Hospital costs
Median $52 791 $92 363
Mean $73 165 $118 415
Range $29 074–91 805 $40 198–136 479 <0.001
Adapted from reference [13].
MSSA, methicillin-susceptible S. aureus; MRSA, methicil-
lin-resistant S. aureus.
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Fig. 4. Inﬂuence of inadequate antibiotic therapy on mor-
tality.
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patient and 4–16 mg/L for isolates collected from
the second patient. Teicoplanin selects ﬁrst-step
mutants or mutants with higher MICs much more
readily than vancomycin and has been associated
with clinical failures [19]. In 1998, Ploy et al. [20]
reported a case in France, from 1995, of a 2-year-
old leukaemic female with MRSA bacteraemia
arising from infected line site. The patient was
unsuccessfully treated with vancomycin (replaced
by teicoplanin) and amikacin, but subsequently
was successfully treated with quinupristin-dal-
fopristin. In 2001, Trakulsomboon et al. [21]
reported a case of a 68-year-old female in Thai-
land with an infected surgical site following total
knee replacement who was treated with vanco-
mycin and teicoplanin; however, treatment failed
and the patient died. In 2000, there was a case of a
41-year-old diabetic male with renal failure,
admitted with bilateral lower limb ischaemia in
Australia [22]. Both lower limbs became gangren-
ous and were amputated. The patient was unsuc-
cessfully treated with teicoplanin, gentamicin and
metronidazole, and then switched to linezolid,
ciproﬂoxacin and metronidazole. The MRSA
cleared and the patient was transferred to a
rehabilitation unit.
The US experience with new antimicrobial
agents
Linezolid
Linezolid is a new oxazolidinone antibiotic used
to treat infections caused by Gram-positive path-
ogens. Clinical trials showed the drug to be very
effective, although resistant enterococcal isolates
were identiﬁed. A total of ﬁfteen cases of linezo-
lid-resistant enterococci were recorded in the
New Drug Application (NDA) database (http://
www.fda.gov/ohrms/dockets/ac/00/backgrd/
3597b1ba.pdf). Six of the resistance cases were
from dose-comparison studies and all were
Enterococcus faecium (four patients received
200 mg q12 h, which is lower than the recom-
mended dose, and two patients received 600 mg
q12 h). A further eight patients infected with
linezolid-resistant E. faecium and one infected
with linezolid-resistant Enterococcus faecalis were
identiﬁed in a compassionate-use programme.
In postmarketing surveys, Gonzales et al. [23]
reported clinical details and antibiotic suscepti-
bility concerning ﬁve patients treated with linezo-
lid for VRE infections who had resistant
organisms isolated (all isolates were E. faecium)
during therapy. Four patients were transplant
patients receiving protracted courses of the drug
and three cases were associated with treatment
failure. In 2003, Rahim et al. [24] reported two
cases of infection caused by E. faecium, resistant to
both linezolid and vancomycin, which occurred
in patients who had not had prior exposure to
linezolid. The report hypothesised that the infec-
tion occurred because of the nosocomial trans-
mission of the co-resistant organism, and this
underscores the importance of infection control
measures in the ﬁght against antimicrobial resist-
ance.
Table 2. Characteristics of Staphylo-
coccus aureus isolates from patients
yielding teicoplanin-resistant organ-
isms
Days from
admission of
index case Sample type
Epidemic
type
MIC (mg/L)
Teicoplanin Linezolid Vancomycin
Case 1
0 Screen E-16 16 4 2
3 Screen E-16 16 2 2
3 Screen E-16 16 4 2
Case 2
)5 Screen E-16 4 2 1
)5 Catheter tip 16D 4 2 1
)3 Screen 16D 4 2 2
9 Screen 16D 4 2 2
22 Tissue wound E-16 16 2 2
23 Screen E-16 16 4 2
24 Environmental E-16 16 2 2
25 Leg E-16 4 2 1
31 Blood E-16 16 2 2
Reproduced from reference [18], with permission.
MIC, minimum inhibitory concentration, determined by agar dilution.
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In-vitro studies have shown that point muta-
tions in the 23S rRNA are associated with linezo-
lid resistance. A good correlation has been
reported between the MIC of linezolid among
enterococci and the number of 23S rRNA gene
copies carrying the T2576 mutation (Table 3) [25].
This is particularly worrying as it suggests that
we could see a steady increase in the number of
linezolid-resistant enterococci.
No cases of linezolid-resistant S. aureus were
reported in the NDA document to the US Food
and Drug Administration (FDA). However, one
case of linezolid-resistant MRSA was reported
postmarketing by Tsiodras et al. [26]. The patient,
who was undergoing peritoneal dialysis, devel-
oped peritonitis. The dialysis catheter was not
removed or replaced and the patient received a
prolonged course of therapy (4 weeks). In addi-
tion, Lee et al. [27] described two cases in which
the prolonged use of linezolid to treat complicated
MRSA infections was followed by the develop-
ment of blurred vision and the progressive loss of
vision and colour perception. In each case, toxic
optic neuropathy was diagnosed and linezolid
therapy was discontinued. The condition resolved
over the ensuing months. Postmarketing surveil-
lance has also identiﬁed a number of cases of
thrombocytopenia and reversible anaemia. This
has lead to the recommendation that complete
blood counts should be monitored weekly in
patients receiving linezolid, particularly in the
case of patients receiving linezolid for longer than
2 weeks, patients with pre-existing myelosuppres-
sion, those receiving concomitant drugs that pro-
duce bone marrow suppression and in patients
with chronic infections [http://www.zyvox.com].
Daptomycin
Daptomycin, a lipopeptide antimicrobial agent,
has a novel mode of action and shows rapid
bactericidal activity against Gram-positive patho-
gens [28–30]. Two recent cases, in which dapto-
mycin was used, at Rush Medical College Faculty
in Chicago follow.
Case studies
The ﬁrst case was a 57-year-old female with renal
transplantation, transferred from another hospi-
tal. The patient was suffering from hypotension
and had a fever of 104F. The patient reported
having fever and chills. Blood cultures drawn on
admission were positive for Gram-positive cocci
in clusters, later conﬁrmed as MRSA. Urine
cultures were negative. Other laboratory results
indicated a WBC of 6.0 · 103/mcL (normal 3.7–
10.5 · 103/mcl), BUN of 2 mg/dL (normal 7–
20 mg/dL) and creatinine of 2.2 mg/dL (normal
0.8–1.4 mg/dL). Trans-thoracic echograph
showed a 14-mm pedunculated vegetation on
the mitral valve. Therapy was started with vanco-
mycin 1 g IV q24 h and gentamicin 55 mg IV
q24 h. Multiple sets of blood cultures were pos-
itive on subsequent days but cleared after 5 days
of therapy, and the patient’s clinical status
Table 3. Correlation between line-
zolid MIC and the estimated number
of 23S rRNA genes containing the
T2576 mutation for clinical isolates
of enterococci
Linezolid
MIC (mg/L)
Number of clinical isolates with indicated number of
T2576 gene copiesa
E. faecium (n ¼ 27) E. faecalis (n ¼ 16)
0–1 1–2 2–3 3–4 4–5 5–6 0–1 1–2 2–3 3–4
1
2 4
4 3 1 4
8 2 1
16 2
32 4 3 2 2
64 2 2 3 2 3
128 1 2
Reproduced from reference [25], with permission.
MIC, minimum inhibitory concentration.
aDetermination by averaging data from three pyrosequencing runs, each
performed with a separate batch of ampliﬁed template DNA and based on six
gene copies of E. faecium and four copies of E. faecalis (http://rrndb.cmc.msu.
edu).
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improved. After 21 days (of a 6-week course of
vancomycin therapy) the patient again experi-
enced fevers and chills, blood cultures again
became positive for MRSA and a transoesopha-
geal echograph showed a 21-mm pedunculated
vegetation on the mitral valve. The patient con-
tinued on vancomycin and was offered, but
refused, surgery to replace the mitral valve. The
patient then experienced embolic events to her
right external ileac, popliteal and distal posterior
tibial arteries as well as the main artery supplying
her transplant kidney. The decision was made to
start daptomycin 6 mg/kg IV q24 h. Blood cul-
tures became negative after 2 days of therapy and
the patient’s condition stabilised. Three days later
the patient was taken for a mitral valve replace-
ment; a culture of vegetation grew MRSA. The
patient was discharged to complete a 6-week
course of daptomycin.
The second case was a 48-year-old male with
non-union left knee fusion following multiple
infections. After debridement and removal of the
orthopaedic prosthesis, the knee became infected
and cultures grew MRSA. The patient was
started on intravenous vancomycin but devel-
oped neutropenia within 10 days. He was
switched to oral linezolid after which the WBC
recovered, but 10 days later he developed
thrombocytopenia. He was then switched to
intravenous daptomycin, whereupon the platelet
count recovered and intravenous daptomycin
was continued at home for 10 weeks. After
8 weeks, the patient was admitted for further
debridement and during that time cultures were
negative.
CONCLUSIONS
Gram-positive organisms, particularly S. aureus
and enterococci, are important pathogens in the
context of health care and in the case of S. aureus,
the emergence of community-acquired isolates is
a worrying development. Numerous studies have
demonstrated the higher mortality and increased
cost associated with MRSA. The advent of MRSA
with resistance to glycopeptides may further limit
treatment options. In addition, the appearance of
pathogens with resistance to the newer agents,
such as linezolid, indicates a growing need for
new antimicrobial agents, with novel modes of
action, for use in the treatment of serious Gram-
positive infections. The case studies presented in
the paper show that daptomycin may fulﬁl this
need.
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